Rana R. McKay, MD, on RCC: Continuing Benefit After Halting Treatment
2017 Genitourinary Cancers SymposiumRana R. McKay, MD, of the University of California, San Diego, discusses study findings on PD-1/PD-L1 responders with metastatic renal cell carcinoma who discontinue therapy for immune-related adverse events. (Abstract 467)
Related Videos
Roland Seiler, MD, on Bladder Cancer: Subtypes and Treatment Response (German Language Version)
Roland Seiler, MD, of the University of British Columbia, discusses in German a way to identify molecular subtypes of muscle-invasive bladder cancer, the varying responses to cisplati...
L. Michael Glodé, MD, on Prostate Cancer: Results From SWOG S9921
L. Michael Glodé, MD, of the University of Colorado Cancer Center, discusses study findings on adjuvant androgen deprivation vs mitoxantrone plus prednisone plus ADT in high-risk pros...
Roland Seiler, MD, on Bladder Cancer: Subtypes and Treatment Response
Roland Seiler, MD, of the University of British Columbia, discusses a way to identify molecular subtypes of muscle-invasive bladder cancer, the varying responses to cisplatin-based ne...
Karim Chamie, MD, on Bladder Cancer: Optimizing Surgical and Medical Therapies
Karim Chamie, MD, of the University of California, Los Angeles, discusses induction and maintenance BCG therapy in non–muscle-invasive bladder cancer.
W. Marston Linehan, MD, on Renal Cell Carcinoma: Genetic Predisposition
W. Marston Linehan, MD, of the National Cancer Institute, discusses the genetic basis of the different types of kidney cancer, which provides the key to clinical management.
